WORLDSymposium 2023 New Treatment Award
In recognition of achieving major milestones, WORLDSymposium will review potential recipients for the New Treatment Award in 2023. This award honors “new treatments” that are viewed as providing value to patients with lysosomal diseases, and general acceptance as evidenced by approval by the U.S. Food and Drug Administration, European Medicines Agency, and other regulatory authorities.
Nominations for this award will be accepted from August 1 to October 31, 2022, and may be submitted for any therapy achieving regulatory approval since the last New Treatment Award was bestowed in 2022. Eligible and verified new treatments will be recognized with the WORLDSymposium 2023 New Treatment Award and, if awarded, will be presented on Saturday, February 25, 2023, at 7:30 AM followed by a full day of Contemporary Forum abstract presentations.
Past Award Recipients:
2022 avalglucosidase alfa-ngpt (Nexviazyme®, Sanofi Genzyme)
2022 pabinafusp alfa (IZCARGO®, JCR Pharmaceuticals)
2018 cerliponase alfa (Brineura™, BioMarin)
2018 vestronidase alfa (MEPSEVII™, Ultragenyx)
2017 migalastat (Galafold™, Amicus)
2016 sebelipase alfa (Kanuma™, Alexion)
2015 eliglustat (Cerdelga™, Sanofi Genzyme)
2015 idursulfase beta (Hunterase®, GC Pharma)
2015 cysteamine bitartrate (PROCYSBI™, Horizon Therapeutics)
2015 elosulfase alfa (Vimizim®, BioMarin)